within Pharmacolibrary.Drugs.ATC.M;

model M01AE08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.6 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,
    adminCount     = 1,
    Vd             = 0.0095,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 12.0
  );

  annotation(Documentation(
    info ="<html><body><p>Pirprofen is a nonsteroidal anti-inflammatory drug (NSAID) of the propionic acid class, structurally related to ibuprofen and used in the past for the treatment of pain and inflammation in musculoskeletal disorders and rheumatoid arthritis. Its use has been discontinued in many countries due to hepatotoxicity concerns.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult individuals. No direct human population data or peer-reviewed publications with full PK models are available, so values are estimated based on class similarity to other NSAIDs and limited summary reports.</p><h4>References</h4><ol><li><p>Todd, PA, &amp; Beresford, R (1986). Pirprofen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. <i>Drugs</i> 32(6) 509–537. DOI:<a href=&quot;https://doi.org/10.2165/00003495-198632060-00003&quot;>10.2165/00003495-198632060-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3539573/&quot;>https://pubmed.ncbi.nlm.nih.gov/3539573</a></p></li><li><p>Brocks, DR, et al., &amp; Jamali, F (1993). Influence of the route of administration on the pharmacokinetics of pirprofen enantiomers in the rat. <i>Chirality</i> 5(2) 61–64. DOI:<a href=&quot;https://doi.org/10.1002/chir.530050204&quot;>10.1002/chir.530050204</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8343343/&quot;>https://pubmed.ncbi.nlm.nih.gov/8343343</a></p></li><li><p>Gerardin, A, et al., &amp; Wagner, WE (1983). Absorption kinetics and model characteristics of orally administered pirprofen. <i>Journal of pharmacokinetics and biopharmaceutics</i> 11(4) 425–433. DOI:<a href=&quot;https://doi.org/10.1007/BF01058959&quot;>10.1007/BF01058959</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6668551/&quot;>https://pubmed.ncbi.nlm.nih.gov/6668551</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M01AE08;
